<?xml version="1.0" encoding="UTF-8"?>
<p>Other drugs in consideration for COVID-19 treatment include Favipiravir and Ivermectin. Favipiravir, which was originally developed for influenza, when compared to Umifenovir (Arbidol), led to shorted latencies to relieve cough and pyrexia in COVID-19 patients [
 <xref rid="B89-viruses-12-01058" ref-type="bibr">89</xref>]. Ivermectin, an FDA-approved broad anti-parasitic drug, has also been reported to have broad antiviral activity. An in vitro study, Caly et al. reported that a single treatment of Ivermectin expressed a significant reduction in SARS-CoV-2 viral load in a 48-h cell culture environment [
 <xref rid="B90-viruses-12-01058" ref-type="bibr">90</xref>].
</p>
